Aquapharm Biodiscovery signs study agreement with AMRI Aquapharm Biodiscovery.

Aquapharm Biodiscovery signs study agreement with AMRI Aquapharm Biodiscovery, a respected marine biotechnology organization, announced today it offers signed a research contract with Albany Molecular Study to identify novel drug-like substances and scaffolds with anti-microbial and anti-inflammatory activity from Aquapharm’s marine natural basic products library produced from its extensive assortment of marine micro-organisms. Aquapharm retains all privileges to compounds caused by the collaboration. Related StoriesData shows romosozumab much better than teriparatide in raising bone power in postmenopausal womenRXi Pharmaceuticals begins Phase 1/2 medical trial in ophthalmologyUsing smart phone to identify diabetes marker in salivaThe collaboration represents a major step-forward for Aquapharm in realising the potential of its unique marine assets and expertise in the Pharmaceutical sector long in bed .

Clinical Advancement Efforts and Important Second Half 2010 Clinical Advancement Milestones We expect to provide outcomes from our ongoing Stage 2b study analyzing RDEA594 in combination with allopurinol in approximately 220 patients not really responding adequately to allopurinol by itself and from our ongoing medical pharmacology studies. We expect to provide outcomes from a Phase 1b dose-ranging research of RDEA594 in conjunction with febuxostat in gout individuals. In coordination with Bayer, we intend to continue to progress RDEA119 in advanced cancer sufferers with different tumor types, as a single agent inside our ongoing Phase 1 study and also in combination with sorafenib of our ongoing Phase 1/2 research. Related StoriesMD Anderson study reveals why chemotherapy medications not effective for most pancreatic cancers patientsViralytics enters into scientific trial collaboration agreement with MSDNew RNA check of blood platelets may be used to detect location of cancer Second Quarter and Year-to-Time 2010 Financial Results By June 30, 2010, we had $103.3 million in cash, cash equivalents, and short-term investments, and $1.8 million in receivables, in comparison to $50.